SOOK IN Jung

Dr. SOOK IN Jung

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
SKSeung ji Kang
Seung ji Kang
SJSOOK IN Jung
SOOK IN Jung
Kang SJ, et al. Infect Chemother. 2020 Jun;52(2):154-164. https://doi.org/10.3947/ic.2020.52.2.154

1 June 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SKSeong Eun Kim
Seong Eun Kim
HJHae Seong Jeong
Hae Seong Jeong
YYYohan Yu
Yohan Yu
SSSung Un Shin
Sung Un Shin
SKSoosung Kim
Soosung Kim
KPKyung-Hwa Park
Kyung-Hwa Park
From 71 laboratory-confirmed cases, we found three presymptomatic patients and 10 entirely asymptomatic infections. In two of the three incubation period patients, the viral titer in the presymptomatic period was very high (Ct value 35 RT-PCR within 14 days after diagnosis. Patients who have COVID-19 may already be infectious before there are symptoms, and 14 days of isolation after diagnosis may be sufficient in entirely asymptomatic cases.

1 October 2015 in Antiviral Therapy
Verified
Journal Article
Closed access
UKUh Jin Kim
Uh Jin Kim
DKDong-Min Kim
Dong-Min Kim
JAJoon Hwan Ahn
Joon Hwan Ahn
SKSeung ji Kang
Seung ji Kang
HJHee-Chang Jang
Hee-Chang Jang
SJSOOK IN Jung
SOOK IN Jung
Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective therapeutic modality to treat severe cases because of the high mortality associated with these. In this study, we report two cases of SFTS with neurological manifestations that fully recovered after a combination treatment consisting of intravenous immunoglobulin and corticosteroid.

1 September 2017 in Journal of Infection
Verified
Journal Article
Closed access
SKSeung Ji Kang
Seung Ji Kang
SKSeong Eun Kim
Seong Eun Kim
UKUh Jin Kim
Uh Jin Kim
HJHee-Chang Jang
Hee-Chang Jang
KPKyung-Hwa Park
Kyung-Hwa Park
SJSOOK IN Jung
SOOK IN Jung

19 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SJSOOK IN Jung
SOOK IN Jung
YKYe Eun Kim
Ye Eun Kim
NYNa Ra Yun
Na Ra Yun
CKChoon-Mee Kim
Choon-Mee Kim
DKDong-Min Kim
Dong-Min Kim
JSJun-Won Seo
Jun-Won Seo
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an acute, febrile, and potentially fatal tick-borne disease caused by the SFTS Phlebovirus. Here, we evaluated the effects of steroid therapy in Korean patients with SFTS. Methods: A retrospective study was performed in a multicenter SFTS clinical cohort from 13 Korean university hospitals between 2013 and 2017. We performed survival analysis using propensity score matching of 142 patients with SFTS diagnosed by genetic or antibody tests. Results: Overall fatality rate was 23.2%, with 39.7% among 58 patients who underwent steroid therapy. Complications were observed in 37/58 (63.8%) and 25/83 (30.1%) patients in the steroid and non-steroid groups, respectively (P < .001). Survival analysis after propensity score matching showed a significant difference in mean 30-day survival time between the non-steroid and steroid groups in patients with a mild condition [Acute Physiology and Chronic Health Evaluation II (APACHE II) score 5 days), and non-steroid groups, were 18.4, 22.4, and 27.3 days, respectively (P = .005). Conclusions: After steroid therapy, an increase in complications was observed among patients with SFTS. Steroid therapy should be used with caution, considering the possible negative effects of steroid therapy within 5 days of symptom onset or in patients with mild disease (APACHE II score <14).

16 August 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
CLChan Mi Lee
Chan Mi Lee
CKChung-Jong Kim
Chung-Jong Kim
SKSeong Eun Kim
Seong Eun Kim
KPKyung-Hwa Park
Kyung-Hwa Park
JBJi Yun Bae
Ji Yun Bae
HKHong Bin Kim
Hong Bin Kim
Although many deaths due to carbapenem-resistant Acinetobacter baumannii (CRAB) bacteraemia occur within a few days after the onset of bacteraemia, risk factors for early mortality (EM) have not been deeply investigated. We aimed to determine the risk factors for EM and the difference between risk factors associated with EM and late mortality (LM) in CRAB bacteraemia. Clinical information on all patients with CRAB bacteraemia in 10 hospitals during a 1-year period was collected. Among the cases with mortality within 30 days, EM and LM were defined as death within 3 and more than 5 calendar days from the first positive blood culture, respectively. In total, 212 CRAB bacteraemia cases were included in the analysis. Of 122 (57.5%) patients with 30-day mortality, EM was observed in 75 (61.5%) patients and LM in 39 (32.0%) patients. The proportion of severe sepsis or septic shock, Pitt score, and Sequential Organ Failure Assessment (SOFA) score was significantly higher in patients with EM than those with LM. Although urinary tract infection as the site of infection and the severity of illness were independent predictors of LM, only factors representing the severity of illness were independent risk factors for EM. Our results suggest that a large proportion of CRAB bacteraemia with high severity progresses to a rapidly fatal course, regardless of the underlying diseases or source of infection. Further studies might be needed to investigate the microbiological factors associated with CRAB and pathogen-host interaction in patients with EM.